Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 4/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4385466 | 0.98 | MAOB (0.53) | TAAR1APPDRD2DRD4DRD3 | |
| SCHEMBL6255090 | 0.93 | MAPT (0.53) | TAAR1APPDRD2DRD4DRD3 | |
| SCHEMBL4030217 | 0.91 | MAPT (0.51) | TAAR1APPDRD2DRD4DRD3 | |
| SCHEMBL15923392 | 0.91 | MAPT (0.51) | TAAR1APPDRD2DRD4DRD3 | |
| SCHEMBL321542 | 0.88 | TAAR1 (0.60) | TAAR1APPDRD2DRD4DRD3 | |
| SCHEMBL991452 | 0.88 | TAAR1 (0.56) | TAAR1 | |
| Hydrazine SCHEMBL17334655 | 0.88 | MAPT (0.49) | TAAR1APPDRD2DRD4DRD3 | |
| SCHEMBL24575116 | 0.87 | CYP1A2 (0.46) | TAAR1APPDRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL1623684 | 0.86 | TAAR1 (0.58) | TAAR1APPMAPTMAOBTDP1 | |
| Bromide SCHEMBL9464051 | 0.86 | TAAR1 (0.58) | TAAR1APPDRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462548-A | Synthesis method of bemefibrate intermediate | 山东辰龙药业有限公司 | 2025-02-18 | — | — | CN | claimed |
| WO-2025098997-A1 | 1,4-BENZOTHIAZEPINES AND RELATED COMPOUNDS WITH CYCLOPROPANOL GROUPS AS MULTI-TARGETED DRUGS | GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN (DE) | 2025-05-15 | — | — | WO | disclosed |
| EP-4548971-A1 | 1,4-BENZOTHIAZEPINES AND RELATED COMPOUNDS WITH CYCLOPROPANOL GROUPS AS MULTI-TARGETED DRUGS | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) | 2025-05-07 | — | — | EP | disclosed |
| CN-119462548-A | Synthesis method of bemefibrate intermediate | 山东辰龙药业有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119462548-A | Synthesis method of bemefibrate intermediate | 山东辰龙药业有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-118994046-A | Preparation method of bemat and application of bemat in tablet | 重庆圣华曦药业股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2023-09-19 | — | — | US | disclosed |
| CN-116735756-A | Detection method for measuring 3-bromopropylamine hydrobromide impurity in peama Bei Teqi starting material by gas chromatography | 天津辰欣药物研究有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20210387980-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | Université de Montréal (CA) | 2021-12-16 | — | — | US | disclosed |
| CN-1845905-A | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO (JP) | 2006-10-11 | — | — | CN | disclosed |
| US-7109226-B2 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20060189667-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | FALCON TECHNOLOGY PARTNERS L.P. | 2006-06-29 | — | — | US | disclosed |
| EP-1661890-A1 | PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Kowa Co., Ltd. (JP) | 2006-05-31 | — | — | EP | disclosed |
| WO-2006055525-A2 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-08-11 | — | — | US | disclosed |
| US-20050101636-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-0183147-A2 | Beta-substituted aminophenethylazol derivatives | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-06-04 | — | — | EP | disclosed |
| US-4366154-A | TRANQUILIZERS; PSYCHOLOGICAL DISORDERS | SANDOZ, INC. (US) | 1982-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | IDH2, TFAM, IDH1 | TAAR1 4509/4885APP 4460/4885DRD2 4868/4885 |
| US-20060189667-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | PPARA, PPARG, PPARD | TAAR1 1973/4885APP 3824/4885DRD2 863/4885 |
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PPM1B, PTPN1, PTPN5 | TAAR1 2129/4885APP 1654/4885DRD2 4843/4885 |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | REN, AGTR1, ACE | TAAR1 1785/4885APP 2709/4885DRD2 2061/4885 |
| US-20210387980-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | IDH2, TFAM, NUTF2 | TAAR1 4375/4885APP 4373/4885DRD2 4869/4885 |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | IDH2, TFAM, NUTF2 | TAAR1 4375/4885APP 4373/4885DRD2 4869/4885 |
| US-20050101636-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | PPARG, PPARA, PPARD | TAAR1 1777/4885APP 1978/4885DRD2 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.